Santaris on target with cardiovascular franchise
This article was originally published in Scrip
Executive Summary
Santaris Pharma has advanced its mRNA targeted drug, SPC5001, into Phase I trials for the treatment of high low-density lipoprotein cholesterol (LDL-C), and expects to report data from the trial by 2012, in line with plans announced earlier this year.